Eruptive keratoacanthomas secondary to nivolumab immunotherapy

Bednarek, Robert; Marks, Katherine; Lin, George

doi:10.1111/ijd.13893

Cited by 16 publications

(12 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Marion FRADET 1 , Vincent SIBAUD 2 , Emilie TOURNIER 3 , Laurence LAMANT 3 , Serge BOULINGUEZ 1,2 , Aurore BRUN 1 , Cecile PAGES 2 and Nicolas MEYER 1,2 Toulouse III University; IUCT-oncopole and CHU de Toulouse, 24 chemin de Pouvourville TSA 30030, FR-31059 Toulouse, 2 Department of Dermatology, IUCT-oncopole, and 4 Inserm UMR 1037-CRCT eruptive keratoacanthoma-like lesions has been reported recently in 7 patients treated with pembrolizumab, and in 5 patients treated with nivolumab (5)(6)(7)(8)(9)(10). Similar to the present case, eruptive keratoacanthoma-like lesions induced by immunotherapy are reported to appear early, between 2 and 18 months after the first infusion.…”

Section: Multiple Keratoacanthoma-like Lesions In a Patient Treated Wmentioning

confidence: 99%

Multiple Keratoacanthoma-like Lesions in a Patient Treated with Pembrolizumab

Fradet¹,

Sibaud²,

Tournier³

et al. 2019

Acta Derm Venereol

View full text Add to dashboard Cite

Section: Multiple Keratoacanthoma-like Lesions In a Patient Treated Wmentioning

confidence: 99%

Multiple Keratoacanthoma-like Lesions in a Patient Treated with Pembrolizumab

Fradet¹,

Sibaud²,

Tournier³

et al. 2019

Acta Derm Venereol

View full text Add to dashboard Cite

“…Although it is not clear why these anticancer drugs cause secondary skin neoplasia, there is a hypothesis that they may induce paradoxical activation of the mitogen‐activated protein kinase pathway in keratinocytes, leading to keratoacanthoma or squamous cell carcinoma 24,25 . Actually, the occurrence of eruptive squamous cell carcinomas or keratoacanthomas associated with ICI is rare, but case reports have increased recently 26–30 . Some of the reported cases have a past history of molecular‐targeted agents or a combination immunotherapy with the Toll‐like receptor 9 agonist 26,27 and other cases have no past history of other chemotherapy 28–30 .…”

Section: Discussionmentioning

confidence: 99%

Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center

Park

Yoon

Lee

et al. 2021

The Journal of Dermatology

View full text Add to dashboard Cite

Programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) inhibitors have demonstrated their efficacy in the treatment of various malignancies. Despite their benefits, their immunomodulatory activities can cause unpredictable cutaneous adverse events (CAE). This study aimed to identify characteristics of CAE in patients treated with PD‐1/PD‐L1 inhibitors through the medical records, photographs, and pathology reports. Fifty CAE occurred in 47 (2.75%) of 1711 patients treated with PD‐1/PD‐L1 inhibitors. Pruritic, psoriasiform, urticarial, and acneiform eruptions were the four most common types. Melanoma patients showed CAE more frequently than other malignancies. Acneiform eruption occurred more often at ages under 60 years. Urticarial eruption appeared earlier, while keratoacanthoma appeared later after immunotherapy. The overall survival times were not significantly different between the two groups with and without CAE by Kaplan–Meier analysis (p = 0.055). Studies on CAE may provide more information to understand these drugs and to help manage the patients.

show abstract

“…Many reports noted a lichenoid or interface dermatitis seen on skin biopsy of KAs. Some suggest that the lichenoid milieu and the enhanced T-cell response caused by PD-1 inhibitors may encourage the development of KAs in predisposed individuals,7, 8 although the mechanism is poorly understood.…”

Section: Discussionmentioning

confidence: 99%